Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 21, 2010

Nacalai to Provide TriLink’s Nucleic Acid Products in Certain Asian Countries

  • Nacalai USA has obtained distribution rights for TriLink BioTechnologies’ modified nucleic acid products in Japan, Singapore, South Korea, and Taiwan. The firm manufactures custom oligonucleotides, modified nucleoside triphosphates, and CleanAmp™ PCR products for the diagnostic and OEM markets.

    TriLink performs custom oligo synthesis and modifications for diagnostic and therapeutic development. It also stocks over 150 modified nucleoside triphosphates including Aminoallyl, Biotin, and 2' Fluoro nucleotides. In addition, it offers specialty modified nucleotides such as bisphosphates, a series of monophosphates, as well as CAP and mCAP.

    CleanAmp products include primers, dNTPs, and amidites. CleanAmp primers contain thermolabile chemical modifications that allow for primer-based Hot Start activation in PCR. These modifications prevent primer extension at the lower temperatures of PCR set-up and manipulation, according to TriLink. A Hot Start thermal activation step removes the modification and generates the corresponding unmodified primer, which supports amplification of the desired target.

    CleanAmp amidites allow a firm with its own oligo-synthesis capabilities to produce its own CleanAmp primers. They can reportedly be used on any DNA synthesizer.

    Founded in 1996 and based in San Diego, TriLink also offers custom chemistry, contract research services, and ISO/QSR compliant cGMP production facilities.


Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Pharmacists and Prescription Drug Misuse Programs

Do you agree that pharmacists should make a greater effort to become more involved with prescription drug-monitoring programs?

More »